3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Breast Neoplasms
7
Prostatic Neoplasms
4
Brain Neoplasms
4
Neoplasms
3
Neoplasm Metastasis
3
Sarcoma
2
Multiple Myeloma
2
Lung Neoplasms
2
Glioma
2
Glioblastoma
2
Gastrointestinal Neoplasms
2
Fatigue
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Hepatocellular
2
Weight Loss
1
Uterine Cervical Neoplasms
1
Thrombocytopenia
1
Symptom Management
1
Stomach Neoplasms
1
Splenomegaly
1
Sexual Dysfunction, Physiological
1
Sex Cord-Gonadal Stromal Tumors
1
Sarcoma, Synovial
1
Rectal Neoplasms
1
Peritoneal Neoplasms
1
Pain
1
Ovarian Neoplasms
1
Oligodendroglioma
1
Neuroendocrine Tumors
1
Neoplasms, Germ Cell and Embryonal
1
Interventions
Doxorubicin
9
Imatinib Mesylate
6
pazopanib
4
Ifosfamide
4
Radiotherapy
3
Gemcitabine
3
Docetaxel
3
pembrolizumab
2
Radiation
2
Neoadjuvant Therapy
2
Biopsy
2
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione
2
selinexor
1
saracatinib
1
sapanisertib
1
ribociclib
1
peposertib
1
liposomal doxorubicin
1
indolepropanol phosphate
1
envafolimab
1
cixutumumab
1
brigimadlin
1
avelumab
1
X-Rays
1
Watchful Waiting
1
TTI-621
1
Sunitinib
1
Specimen Handling
1
Razoxane
1
Radiotherapy, Intensity-Modulated
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Dermatofibrosarcoma
×
Quality of Life
×
Clear all
NCT07169344
2026-01-28
PROSARC-1
Oslo University Hospital
Phase 2
Recruiting
110 enrolled